[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632894":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":30,"responsibleParty":47,"collaborators":51,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":26,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":26,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":26,"overallStatus":73,"whyStopped":26,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Liaquat University of Medical & Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Escherichia coli 5C (Colipral®)","EXPERIMENTAL","Participants in this arm will receive Colipral® (dietary supplement containing Escherichia coli 5C), administered twice daily, with 1 capsule in the morning and 1 capsule in the evening after dinner, for 14 days immediately following colonoscopy.",[13],"Dietary Supplement: Colipral®",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants in this arm will receive placebo, identical in appearance but not containing the probiotic strain, administered twice daily, with 1 capsule in the morning and 1 capsule in the evening after dinner, for 14 days immediately following colonoscopy.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Colipral®","Dietary supplement containing Escherichia coli 5C (Colipral®)",[9],null,{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Matching placebo",[15],[31],{"facility":32,"status":26,"city":33,"state":26,"zip":26,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"University of Urbino Carlo Bo, Urbino, Italy","Urbino","Italy","IT",{"type":37,"coordinates":38},"Point",[39,40],12.63633,43.72621,{"lat":40,"lon":39},[43],{"name":44,"role":45,"phone":26,"phoneExt":26,"email":46},"Prof. Davide Sisti, PhD","CONTACT","davide.sisti@uniurb.it",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dr. Amjad Khan","Professor",[52],{"name":53,"class":6},"University of Urbino \"Carlo Bo\"","100632894","effect-of-escherichia-coli-5c-colipral-on-post-colonoscopy-gastrointestinal-symptoms-100632894",false,"NCT07519616","Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms","Evaluation of the Effectiveness of Escherichia Coli 5C in the Management of Post-Colonoscopy Symptoms: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Complete diagnostic colonoscopy with achievement of the cecal fundus\n* Accepted written informed consent for study participation obtained prior to the start of the study\n\nExclusion Criteria:\n\n* Chronic inflammatory bowel disease\n* Complicated Diverticular Disease (DICA \\>3)\n* Suspected or known colorectal malignancy on index colonoscopy\n* Diagnosed microscopic colitis\n* Operative colonoscopy\n* Severe chronic gastrointestinal symptoms judged by the investigator to interfere with the evaluation of study endpoints\n* Subjects who are immunosuppressed or on systemic immunosuppressive treatment, including patients with primary or acquired immunodeficiency, oncological disease on active treatment with chemotherapy\u002Fimmunotherapy, or autoimmune diseases on immunosuppressive treatment\n* Taking probiotics, prebiotics, or synbiotics within 2-4 weeks prior to enrollment\n* Antibiotic therapy within 4 weeks prior to enrollment\n* Lack of acceptance of written informed consent","ALL","18 Years","80 Years",{"count":65,"type":66},160,"ESTIMATED","INTERVENTIONAL",[69],"NA","This prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of Escherichia coli 5C (Colipral®) in adult patients undergoing diagnostic colonoscopy. Participants will be randomized in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately after colonoscopy. The study aims to determine whether Colipral® reduces post-colonoscopy gastrointestinal symptoms compared with placebo, using validated symptom and stool assessment tools, patient-reported global improvement, and safety monitoring.",[72],"Post-Colonoscopy Gastrointestinal Symptoms","NOT_YET_RECRUITING","2026-04-02",{"date":76,"type":77},"2026-04-09","ACTUAL",{"date":79,"type":66},"2026-04-27",{"date":81,"type":66},"2026-10-30",{"name":5,"class":6},1]